Definitely, the PI3K/AKT/mTOR pathway will become a possible pharmaceutical target in the fight against primary brain tumors; countering the abnormal function of one of these factors could lead to a valid therapeutic approach in the glioblastoma contest. Here, MTOR is linked to glioblastoma.